Literature DB >> 11029093

Multiphase helical CT findings after percutaneous ablation procedures for hepatocellular carcinoma.

O Catalano1, M Esposito, A Nunziata, A Siani.   

Abstract

BACKGROUND: Multiple-phase helical computed tomography (CT) has been regarded as the method of choice in the evaluation of patients with hepatocellular carcinoma (HCC) treated by nonsurgical procedures. The aim of this article was to report our experience in the assessment of nodular and parenchymal changes recognizable after various percutaneous ablation therapies.
METHODS: We reviewed the studies of 116 consecutive patients with HCC treated with multisession percutaneous ethanol injection (56 patients, 98 nodules), single-session percutaneous ethanol injection (14 patients, 31 nodules), radiofrequency thermal ablation (32 patients, 48 nodules), and interstitial laser photocoagulation (14 patients, 25 nodules). CT had been performed 3-28 days after the last session (mean = 18 days) with unenhanced helical acquisition and with contrast-enhanced double- or triple-phase helical acquisition.
RESULTS: Persisting neoplastic tissue was identified within 54.5% of the nodules. It was located centrally in 4.5% of these nodules, peripherally in 11%, and eccentrically in 84.5%, and its shape was crescent in 58%, globular in 24.5%, and other in 16%. On arterial phase scans, viable tumor was hyperdense in 97% of the lesions and isodense in 3%; on portal phase scans, the tumor was hyperdense in 20%, isodense in 28%, and hypodense in 52%; on delayed phase scans, the tumor was consistently hypodense. Tumor necrosis was always hypodense on contrast-enhanced scans. On unenhanced images, 7.4% of the nodules were undetectable. Nodule diameter appeared as unchanged in 53% of the nodules and as larger in 47%; its shape was unchanged in 54% and modified in 46%; its margins were unchanged in 36% and modified in 64%. A rim of granulation tissue was detected around 15% of the nodules, and a perilesional transient attenuation difference was detected in 21%. Perihepatic effusion was seen in 13% of the patients, segmental biliary duct dilation and local atrophy each in 9%, arterioportal fistula in 6%, portal vein thrombosis, subcapsular collection and pleural effusion each in 7%, hepatic infarction in 5%, and inferior vena cava thrombosis in 2%.
CONCLUSION: Percutaneous ablation of HCC may cause several changes. Knowledge of their CT appearance is mandatory to correctly assess and manage this tumor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11029093     DOI: 10.1007/s002610000076

Source DB:  PubMed          Journal:  Abdom Imaging        ISSN: 0942-8925


  10 in total

Review 1.  Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; Flora Hau-Fung Tsang; John Wong
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

Review 2.  Hepatocellular carcinoma treated with interventional procedures: CT and MRI follow-up.

Authors:  Yong-Song Guan; Long Sun; Xiang-Ping Zhou; Xiao Li; Xiao-Hua Zheng
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

3.  Percutaneous radiofrequency ablation of hepatocellular carcinomas adjacent to the gallbladder with internally cooled electrodes: assessment of safety and therapeutic efficacy.

Authors:  Sang Won Kim; Hyunchul Rhim; Mihyun Park; Heejung Kim; Young-sun Kim; Dongil Choi; Hyo K Lim
Journal:  Korean J Radiol       Date:  2009-06-25       Impact factor: 3.500

4.  Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors.

Authors:  Cheng William Hong; Lucy Chow; Evrim B Turkbey; Riccardo Lencioni; Steven K Libutti; Bradford J Wood
Journal:  Cardiovasc Intervent Radiol       Date:  2015-07-31       Impact factor: 2.740

5.  Ablation of large HCCs using a new saline-enhanced expandable radiofrequency device().

Authors:  L Tarantino; I Sordelli; V Nocera; A Piscopo; C Ripa; D Parmeggiani; P Sperlongano
Journal:  J Ultrasound       Date:  2009-04-02

6.  Rapid progression of hepatocellular carcinoma after Radiofrequency Ablation.

Authors:  Andrea Ruzzenente; Giovanni De Manzoni; Matteo Molfetta; Silvia Pachera; Bruno Genco; Matteo Donataccio; Alfredo Guglielmi
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

7.  Percutaneous radiofrequency ablation of hepatocellular carcinoma in the presence of portal vein thrombosis.

Authors:  Ziv Neeman; Steven K Libutti; Jay W Patti; Bradford J Wood
Journal:  Clin Imaging       Date:  2003 Nov-Dec       Impact factor: 1.605

Review 8.  Percutaneous radiofrequency ablation of lung tumors with expandable needle electrodes: current status.

Authors:  A D Kelekis; L Thanos; S Mylona; N Ptohis; K Malagari; A Nikita; J Christodoulidou; N Kelekis
Journal:  Eur Radiol       Date:  2006-05-16       Impact factor: 7.034

Review 9.  Local ablation therapy with contrast-enhanced ultrasonography for hepatocellular carcinoma: a practical review.

Authors:  Tae Kyoung Kim; Korosh Khalili; Hyun-Jung Jang
Journal:  Ultrasonography       Date:  2015-06-24

Review 10.  Post-treatment imaging of liver tumours.

Authors:  Wolfgang Schima; Ahmed Ba-Ssalamah; Amir Kurtaran; Martin Schindl; Thomas Gruenberger
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.